G(M2) Ganglioside — A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis
Citation(s)
A Dose-Escalated, Double-Blind, Placebo-Controlled, Randomized Phase I Clinical Trial of Pyrimethamine in Patients Affected With Chronic GM2 Gangliosidosis (Tay-Sachs or Sandhoff Variants)